Global stock

NASDAQUSD

Immunovant

IMVT

AI analysis and articles are in Czech.

§ Financial healthLong-term stability

35/ 100

Overall score·IMVT

Current price

28.17USD

26/10/2026

P/E, P/B

Valuation

Weak

Rates whether the stock is cheap or expensive relative to its history and sector. A score above 60 suggests the stock trades below its estimated intrinsic value.

Tracks:P/E · P/B · FCF yield · sector

Tradiční ocenění je obtížné kvůli zápornému EPS a chybějícímu P/S; P/B 7,9 a záporný forward P/E ukazují na vysoké ocenění vzhledem k dosavadní ziskovosti. Potenciál růstu stojí na klinickém vývoji, zatímco slabými stránkami jsou ztrátovost, riziko financování a cena pod 50denním i 200denním průměrem.

§ Outlook vs S&P 500Next 12 months

Probably not

Estimated chance of beating the index: about 44%

8 of 8 inputs

NoProbably notSameProbably yesYes

A model estimate from current values. The result may change with new data; it is not a price target or an investment recommendation.

§ Context and events

Management

Eric Venker je CEO a člen představenstva; Frank M. Torti zastává funkci výkonného předsedy představenstva. Tiago M. Girao vede finance a Melanie Gloria provoz. Strategie společnosti spočívá ve vývoji léčiv pro autoimunitní onemocnění, především kandidátů zaměřených na FcRn, a v postupu těchto programů klinickým vývojem.

Articles about Immunovant, in Czech (0)

No articles yet. New analyses are published daily.

§ Upcoming results

9 November 2026

in 13 days

Earnings

Earnings = quarterly financial results (revenue and profit). Companies publish them every three months and the share price often reacts strongly.

§ Frequently asked questions

What is Immunovant (IMVT)?

Immunovant (IMVT) is a global stock traded on NASDAQ. Sector: Healthcare. We track it daily — scoring news sentiment, the short-term outlook and long-term stability on a 0–100 scale.

What is the Immunovant price today?

As of 26 October 2026, Immunovant trades at about 28.17 USD per unit. We update the price daily from public market data. Intraday moves can differ significantly — always check the final price with your broker.

How to buy Immunovant?

Through regulated online brokers such as Degiro, XTB, Trading 212 or Interactive Brokers. Shares trade in USD or EUR — most brokers convert your currency automatically. FinSignal does not operate any of these platforms and charges no commission — the overview is only a signpost.

Does Immunovant pay a dividend?

Immunovant either pays no dividend at the moment or we have no reliable data on it. Many growth companies prefer reinvesting profit to paying dividends — check the current policy in the company's investor relations materials.

Is Immunovant a good investment in 2026?

Our AI signal currently rates Immunovant as strongly negative (score 26/100). Financial health comes out at 35/100, so beyond short-term news it is worth watching the valuation, growth, profitability and stability of the company. FinSignal is not an investment adviser licensed under Czech Act No. 256/2004 Coll. — signals are analytical input, not a recommendation to buy or sell. You make every decision at your own risk.

§ More global stocks

Microsoft Corporation

MSFThealth 73/100

§ How to buy Immunovant

You can buy shares through regulated online brokers available in the EU. They differ mainly in fees, app quality and which markets they cover.

Degiro
Dutch broker with low fees for passive investors. No account fee, trading in EUR and USD.
XTB
Polish broker with zero commission on stocks and ETFs up to EUR 100,000 a month. Own xStation platform.
Trading 212
Zero-commission broker with fractional shares from EUR 1 and automated investing (Pies). Suits beginners and regular investing.
Interactive Brokers
US broker for advanced investors. The widest choice of markets, low costs at larger volumes, a professional platform with a steeper learning curve.

FinSignal operates none of these platforms. We charge no commission on purchases.

Important: Signals are an analytical tool, not investment advice within the meaning of Czech Act No. 256/2004 Coll. Past performance does not guarantee future results. You make all decisions at your own risk.

§ Current signalShort-term mood

/ 100

● Strongly negative

Earnings in 13 days

On 9 November 2026 the company publishes its quarterly results. This period tends to bring large price moves — the signal below does not reflect the results yet.

News summary

No newer news

Signal 11/10, 12:01

Akcie IMVT 8. října 2026 klesly po neúspěchu studie Sjögrenova syndromu u společnosti argenx, což může zatížit sentiment vůči příbuzné lékové třídě. Dopad na Immunovant by byl omezený, pokud se obavy nepotvrdí v jeho vlastních datech či vývoji akcie.

Zpráva přímo uvádí IMVT jako akcii zasaženou neúspěchem studie argenx, avšak její obsah není ověřen a nedokládá problém s vlastním kandidátem Immunovantu. Krátkodobý technický obraz je výrazně slabý: cena klesla o 9,37 % za 7 dní a 20,03 % za 30 dní, při klesajícím trendu, momentu 10 a RSI 16. RSI značí přeprodanost, ale sama o sobě nepotvrzuje obrat; střednědobý pohled zůstává nejistý vzhledem k nedostatku firemních fundamentálních údajů.

Risks: Pokračující pokles může odrážet přetrvávající tlak na sektor a udržet slabý krátkodobý výhled; naopak stabilizace ceny a vlastní pozitivní klinická data Immunovantu by tento signál oslabily. Protože podklad neověřuje podrobnosti studie ani přímý dopad na portfolio IMVT, jeho relevance může být menší, než naznačuje titulek.

More about the signal

Signal history· 2

05/1008:5335 · Slightly negative
Immunovant v poslední době čelí nejistotě po jednom selhání v klinické fázi; makro prostředí a technická korelace naznačují možné oslabení ceny.
28/0918:0122 · Strongly negative
Immunovant čelí výraznému cenovému tlaku a slabému technickému nastavení; krátkodobě se může objevit další tlak na cenu.

The full 90-day signal history is part of Premium.

Ask the AI

DCF valuation

A DCF model is not suitable for this asset class.

§ Valuation check

Is the price reasonable?

Six quick tests: price against fair value, the last year, similar companies and analyst estimates. They are calculated from the numbers, not from AI estimates. This is not a recommendation.

Data 12 of 18

Valuation score

2/ 6

2/6 tests available

1. Below DCF fair value

The complete DCF range or the current price is missing.

2. Well below DCF value

The complete DCF range or the current price is missing.

3. Price vs. the last year

24% above the 1-year low (22.98 USD to 44.96 USD), based on stored daily prices.

4. P/E vs. similar companies

The sector sample has only 72 companies; scoring needs at least 8.

5. P/E relative to growth

PEG or a reliable growth input is not available.

6. Analyst price target

73.5% vs. the current price, 16 analysts.

Price and fair value

no complete range

The DCF check appears once both the price and the model range are available.

Price vs analyst target

Current price

28.17 USD

Low 30.00 USDHigh 66.00 USD

Current priceAverage: 48.88 USD

DCF gap

no complete range

The DCF check appears once both the price and the model range are available.

Analyst target

+73.5%

Average target 48.88 USD vs. price 28.17 USD.

Analyst consensus

Target range

30.00 USD - 66.00 USD

Coverage

16 analysts

Analyst consensus

1.6 / 5

Changes 180 d

+0 / -0

EPS next year

3.2%

Revenue next year

0.0%

Valuation multiples

-10.2

7.9

-8.9

52-week range24% above the low

22.98 USD44.96 USD

0.0%

-80.1%

Price vs 50D-21.2%

Price vs 200D-11.9%

Metrics explained+

Price and fair value

DCF range: A model estimate of fair value from future free cash flow. A price above the range means the market pays a premium over the model; a price below it may signal a more conservative market valuation or an overly optimistic model.
Analyst target: The average and range of the analyst price targets we track. It is the market consensus, not a FinSignal recommendation, and it can lag fast price moves.
52-week range: Shows where the current price sits between the low and high of the last year. A value near the high often signals strong momentum, but on its own says nothing about whether the stock is expensive.
Price vs 50D / 200D: Compares the price with its short- and long-term moving averages. A positive value means the price is above the trend; a negative one below it.

Multiples

P/E: Price relative to current earnings. A lower P/E can mean cheaper, but it can also point to a weak outlook or risk.
Forward P/E: Price relative to next year's expected earnings. For growing companies it is often more useful than the historical P/E because it reflects estimates of future earnings.
P/B: Price relative to the book value of equity. It makes more sense for banks, insurers and capital-intensive companies than for software or brands.
P/S: Price relative to revenue. It helps with companies that have low or negative earnings; a high P/S means the market expects strong growth or future margins.
EV/EBITDA: The value of the whole company, including debt, relative to operating profit before depreciation. Useful for comparing companies with different leverage.
PEG: P/E adjusted for earnings growth. A value around 1 may suggest the valuation matches growth, but the metric is sensitive to estimates.

Growth and quality

EPS growth: Year-on-year change in earnings per share. Strong growth supports a higher valuation, but for cyclical companies it can be temporary.
Revenue growth: The growth rate of sales. It helps tell whether profits grow on real demand or mainly on cost savings.
Net margin: How much of each unit of revenue is left as net profit. A higher margin often points to stronger pricing power or more efficient operations.
ROE: Return on equity. A high ROE can signal a quality business, but check that it is not artificially boosted by heavy debt.

Some data missing. Missing values mean the market data source did not provide them for this ticker. The data is indicative and may be delayed. Price as of 26/10/2026.

Management and competitive advantage

Both are estimated by the AI from the company profile, news and results. They do not count towards the 6-pillar financial health score. The AI comments are in Czech.

weak

Zkušený tým rozvíjí zaměřenou klinickou strategii, avšak velmi vysoké uvedené governance riziko v oblasti představenstva, odměňování a práv akcionářů skóre snižuje.

mixed

Kandidáti zaměření na FcRn mohou nabídnout diferenciaci v léčbě autoimunitních onemocnění, ale klinická fáze a absence širokého komerčního portfolia zatím nepředstavují prokázanou trvalou konkurenční výhodu.

Information

Type: Global stock
Symbol: IMVT
Exchange: NASDAQ
Currency: USD
Sector: Healthcare
: 5.8B USD
: 0.84

§ Risk profile

Společnost je ve fázi klinického vývoje a její hodnota závisí na účinnosti a bezpečnosti kandidátních léčiv. Neúspěšné studie, regulatorní překážky nebo potřeba dalšího financování mohou vést k prudkému poklesu ceny akcie či k naředění podílů stávajících akcionářů.

Ask the AI about Immunovant All signals